Discernible improvements have taken place in soft tissue sarcoma patient survivorship and quality of life over the past 20 years, with overall 5-year survival currently at approximately 50%. Shifts in treatment have taken place over the past decade, from single-modality treatment involving radical surgery to sophisticated limb-salvage strategies combined with radiation therapy and protocol-administered chemotherapy.
To identify patterns of treatment and outcome, all soft tissue sarcoma cases diagnosed in 1988 and 1993 as recorded in the National Cancer Data Base were analyzed on the basis of histology and anatomic site.
There was an increase in sarcomas originating in the pleura with a concurrent increase in mesotheliomas.
A shift toward more advanced disease was also noted.
Limb-sparing surgical procedures are now standard.
However, it appears from stage subset analysis that many Stage II and III patients are under-treated due to lack of multimodality therapy usage.
Use of pretreatment multimodality planning conferences will increase the likelihood that stage-appropriate combinations of surgery, radiation therapy, and chemotherapy will be used.
In turn, election of multimodality approaches should increase the possibility of improved overall and disease free survival in the future.
Mots-clés Pascal : Sarcome, Partie molle, Homme, Modalité traitement, Pronostic, Survie, Epidémiologie, Echelon national, Etats Unis, Amérique du Nord, Amérique, Tumeur maligne
Mots-clés Pascal anglais : Sarcoma, Soft tissue, Human, Application method, Prognosis, Survival, Epidemiology, National scope, United States, North America, America, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0013337
Code Inist : 002B08A. Création : 21/05/1997.